CG
CRBP icon

Carmignac Gestion’s Corbus Pharmaceuticals CRBP Stock Holding History

Carmignac Gestion’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-125,781
Closed -$31.7M – 135
2020
Q2 		$31.7M Buy
125,781
+101,388
+416% +$20.5M 0.44% 46
2020
Q1 		$3.83M Buy
+24,393
New +$4.12M 0.07% 65

Other funds holding CRBP

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Carmignac Gestion's CRBP Position: Q3 2020 in Review

Carmignac Gestion sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 125,781 shares — an estimated $31.7M sold.

Carmignac Gestion first reported a position in CRBP in Q1 2020 and held it in 2 quarters. The position peaked at $31.7M in Q2 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

  • Carmignac Gestion reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Carmignac Gestion sold 125,781 Corbus Pharmaceuticals shares in Q3 2020, an estimated $31.7M.
  • Carmignac Gestion first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Carmignac Gestion's Corbus Pharmaceuticals position peaked at $31.7M in Q2 2020.
  • 122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Carmignac Gestion's 13F filing for Q3 2020, filed 13 Nov 2020.